Company Overview and News

 
Tlou Energy to spud first production well at Lesedi next month

2018-09-19 proactiveinvestors.com.au
Tlou Energy Ltd (LON:TLOU) managing director Tony Gilby and general manager Solomon Rowland chat to Proactive's Andrew Scott following an update on operations at the Lesedi coalbed methane project.
TLOU TOU

 
Tlou Energy gearing up for October drilling

2018-09-17 proactiveinvestors.com.au
Tlou Energy Ltd (LON:TLOU) has updated on its operations at the Lesedi coal bed methane project, where it is gearing up for a well in October.
TLOU TOU

 
Tlou Energy: Closing date extended for CBM power proposal

2018-09-06 proactiveinvestors.com.au
Tlou Energy Ltd (LON:TLOU) told investors that the closing date has been extended for proposals in the process for the coal-bed-methane fuelled power project in Botswana.
TLOU TOU

 
Tlou Energy reports on “very productive year”

2018-08-30 proactiveinvestors.com.au
Tlou Energy Limited (LON:TLOU) managing director Tony Gilby, in today’s final results statement, described “a very productive year” for the company.
TLOU TOU

 
Tlou Energy says drilling could start at Lesedi in September

2018-08-13 proactiveinvestors.com.au
Tlou Energy Ltd (LON:TLOU) told investors that the first well of its proposed pilot coal bed methane project is expected to spud in September.
TLOU TOU

 
Tlou Energy set to re-tender for Botswana

2018-07-27 proactiveinvestors.com.au
Tlou Energy Ltd (LON:TLOU) has told investors that it is one of two companies that have been invited to re-tender for a coal-bed-methane fueled power projects in Botswana.
TLOU TOU

 
Tlou Energy continues efforts to advance gas-to-power assets

2018-07-25 proactiveinvestors.com.au
Tlou Energy Ltd (LON:TLOU), in its quarterly update, reminded investors that it is working to secure a clear pathway towards a gas-to-power pilot project in Botswana.
TLOU TOU

 
Tlou Energy says core drilling rig has arrived for Lesedi project

2018-07-18 proactiveinvestors.com.au
Tlou Energy Ltd (LON:TLOU) told investors on Wednesday that its core drilling rig has arrived on site of the Lesedi coal bed methane (CBM) project in Botswana.
TLOU TOU

 
Tlou Energy updates on RFP re-tender and plans for Lesedi drilling

2018-07-05 proactiveinvestors.com.au
Tlou Energy Limited’s (LON:TLOU) Colm Cloonan and executive director Gabaake Gabaake spoke to Proactive’s Andrew Scott from Botswana.
TLOU TOU

1
Tlou Energy plans production well drilling at Lesedi for third quarter of 2018

2018-06-28 proactiveinvestors.com.au
Tlou Energy Limited (LON:TLOU ASX:TOU) said it is currently planning a drilling programme for production wells at its Lesedi coal bed methane (CBM) project to start in the third quarter of this year.
TLOU TOU

1
TLOU Energy raises capital to accelerate CBM well plans

2018-06-06 proactiveinvestors.com.au
TLOU Energy Ltd (LON:TLOU) has confirmed a £1.4mln share placing and launched a further share offer seeking to raise a further £3.2mln of new capital.
TLOU TOU

1
Tlou Energy continues to advance Botswana CBM projects

2018-04-23 proactiveinvestors.com.au
Tlou Energy Ltd (LON:TLOU) updated investors on its activities in the three months ended March 31, in which the company focussed on the Lesedi and Mamba coal bed methane (CBM) projects in Botswana.
TLOU TOU

1
Tlou Energy’s Tony Gilby in Botswana to advance grid connection discussions

2018-03-15 proactiveinvestors.com.au
Tlou Energy Ltd's (LON:TLOU) Tony Gilby updates Proactive's Andrew Scott on the re-tendering process with the government in Botswana.
TLOU TOU

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:TOU / TLOU ENERGY LIMITED on message board site Silicon Investor.

MicroTouch (MTSI): at or near bottom? MicroTouch (MTSI): at or near bottom? MicroTouch (MTSI): at or near bottom? Neonode(NEON)-With A Soft Touch in My Heart and Other Places Neonode(NEON)-With A Soft Touch in My Heart and Other Places Neonode(NEON)-With A Soft Touch in My Heart and Other Places
Cramer Touts Cramer Touts Cramer Touts AirTouch designed the SmartLinX product for Telmex? AirTouch designed the SmartLinX product for Telmex? AirTouch designed the SmartLinX product for Telmex?
A robot with a healing touch A robot with a healing touch A robot with a healing touch CommTouch (CTCH) : a futur Media Metrix Top 10 ? CommTouch (CTCH) : a futur Media Metrix Top 10 ? CommTouch (CTCH) : a futur Media Metrix Top 10 ?
The GUMMMy Bear Squad touting Gum Tech (NASDAQ: GUMM) The GUMMMy Bear Squad touting Gum Tech (NASDAQ: GUMM) The GUMMMy Bear Squad touting Gum Tech (NASDAQ: GUMM) Vodafone-Airtouch (NYSE: VOD) Vodafone-Airtouch (NYSE: VOD) Vodafone-Airtouch (NYSE: VOD)
TouchStone S/W (TSSW) TouchStone S/W (TSSW) TouchStone S/W (TSSW) BMGX--New Tout via snail mail boxes July 05 BMGX--New Tout via snail mail boxes July 05 BMGX--New Tout via snail mail boxes July 05